13F Holdings
中文EN

SILO Silo Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1514183 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY26.7%
TTM EPS YoY159.8%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,534.1%
Net margin-10,319.0%
FCF margin—
EBITDA margin—

Returns

ROE-55.3%
ROA-49.0%
ROIC (approx.)-207.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets4.0%
Debt / equity0.00x
Current ratio24.43x
Interest coverage-112.82x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY2021*2021-12-31
Income statement
Revenue$72,102$72,102$72,102$72,102$71,264
Cost of revenue$44,295$5,838$5,838$5,838$5,004
Gross profit$27,807$66,264$66,264$66,264$66,260
R&D expense$2.16M$2.37M$845,092$1.29M$693,910
SG&A expense——$390,071$227,259$162,953
Operating income-$4.28M-$4.71M-$3.86M-$3.63M-$2.74M
Interest expense$37,302$5,084$4,869$2,199$3,036
Pretax income-$4.23M-$4.39M-$3.63M-$3.91M$4.18M
Income tax————$24,876
Net income-$4.23M-$4.39M-$3.70M-$3.91M$3.90M
EPS (basic)-0.50-1.19-1.20—0.04
EPS (diluted)-0.50-1.19-1.20—0.04
Weighted avg. shares (diluted)8.38M3.68M3.08M2.28M1.92M
Banking
Net interest income————-$3,036
Balance sheet
Cash & equivalents$4.75M$3.91M$3.52M$11.37M$9.84M
Short-term investments$2.11M$3.17M$4.14M——
Receivables———$66,010—
Inventory————$26,659
Current assets$7.39M$7.11M$7.68M$11.57M$10.40M
Intangibles$217,375$241,215———
Total assets$7.61M$7.41M$7.75M$11.64M$10.49M
Current liabilities$650,183$1.66M$775,590$436,318$490,039
Total liabilities$1.30M$2.38M$1.57M$1.30M$1.43M
Shareholders' equity$6.31M$5.03M$6.18M$10.34M$9.06M
Shares outstanding887,8864.48M2.91M3.16M1.97M
Cash flow statement
Operating cash flow-$4.66M-$3.83M-$3.22M-$3.50M-$2.28M
Investing cash flow$644,021$973,777-$4.15M$86,707$7.19M
Financing cash flow$4.86M$3.24M-$471,121$4.94M$3.79M
Stock-based compensation$117,021$0$871,625$577,651$395,123

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.